Amarin Corporation plc (ADR)  

(Public, NASDAQ:AMRN)   Watch this stock  
Find more results for Joseph M Aaron�
-0.05 (-3.70%)
Pre-market: 1.26 -0.04 (-3.08%)
Sep 22, 8:10AM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.27 - 1.36
52 week 1.27 - 7.39
Open 1.35
Vol / Avg. 7,780.00/3.35M
Mkt cap 226.37M
P/E     -
Div/yield     -
EPS -0.45
Shares 174.13M
Beta 0.80
Inst. own 37%
Sep 16, 2014
Amarin Corporation PLC Conference Call to discuss its commitment to the REDUCE-IT study
Sep 10, 2014
Amarin Corporation PLC at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 121.55% -630.82%
Operating margin 101.49% -691.08%
EBITD margin - -678.95%
Return on average assets 28.85% -59.02%
Return on average equity - -
Employees 185 -
CDP Score - -


2 Pembroke House Upper Pembroke Street 28-32, Dublin 2
+353-1-6699020 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Amarin Corporation plc (Amarin) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company�s product candidate is AMR101, an ultra-pure omega-3 fatty acid. It is developing AMR101 for the treatment of patients with high triglyceride levels, or hypertriglyceridemia. In September 2011, it filed a New Drug Application (NDA), with the United States Food and Drug Administration (FDA). In December 2011, it commenced patient dosing in its cardiovascular outcomes study of AMR101, titled REDUCE-IT (Reduction of Cardiovascular Events with eicosapentanoic acid (EPA) - Intervention Trial).

Officers and directors

Lars G. Ekman M.D., Ph.D. Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
John F. Thero CPA President, Chief Executive Officer, Assistant Secretary, Director
Age: 53
Bio & Compensation  - Reuters
Michael J. Farrell Principal Financial Officer and Principal Accounting Officer
Age: 36
Bio & Compensation  - Reuters
Stephen B. Ketchum Ph.D. President - Research and Development, Senior Vice President
Age: 49
Bio & Compensation  - Reuters
Joseph T. Kennedy J.D. Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
Age: 46
Bio & Compensation  - Reuters
Aaron D. Berg Senior Vice President - Marketing and Sales
Bio & Compensation  - Reuters
Joseph S. Zakrzewski Director
Age: 51
Bio & Compensation  - Reuters
David M. Stack Independent Director
Age: 62
Bio & Compensation  - Reuters
James I. Healy M.D, Ph.D. Non-Executive Independent Director
Bio & Compensation  - Reuters
Patrick J. O'Sullivan Non-Executive Independent Director
Age: 72
Bio & Compensation  - Reuters